Rosa Gini

Sep 4, 2024 | onlinelibrary.wiley.com | John Tazare |Shirley Wang |Rosa Gini |Daniel Prieto-Alhambra

This study aimed to quantify current trends of programming code sharing in pharmacoepidemiology research and provide recommendations on this topic. Out of 968 eligible “Pharmacoepidemiology and Drug Safety” articles between 2017 and 2022, 4.8% (N = 46) shared programming code. Code sharing increased from 1.8% in 2017 to 9.5% in 2022, with higher prevalence in methodological and simulation studies.

Aug 15, 2024 | onlinelibrary.wiley.com | Rosa Gini |Romin Pajouheshnia |Morris A. Swertz |Lia Gutierrez

1 Introduction In November 2020, the MINERVA (Metadata for data dIscoverability aNd study rEplicability in obseRVAtional studies) project (EUPAS39322) was initiated in response to the Heads of Medicines Agencies–European Medicines Agency (HMA–EMA) joint Big Data Task Force recommendation on “the identification of metadata” for regulatory decision-making on the choice of data source [1-3].

May 9, 2024 | onlinelibrary.wiley.com | Rosa Gini |Romin Pajouheshnia |Helga Gardarsdottir |Dimitri Bennett

Key Points This is the first systematic exploration of approaches to describe diversity across data sources generating RWE, and the challenges and opportunities implied by such diversity. The review identified 91 documents offering recommendations and examples for characterizing diversity, or leveraging data diversity in pharmacoepidemiologic research. Our scoping review provides the basis for a framework to characterize data sources used to generate RWE.

Oct 13, 2023 | headachejournal.onlinelibrary.wiley.com | Giulia Hyeraci |Olga Paoletti |Luigi Iannone |Rosa Gini

CONFLICT OF INTEREST STATEMENT Giulia Hyeraci, Olga Paoletti, Rosa Gini, and Giuseppe Roberto are employed by/consultants of ARS, a public health agency that conducts or participates in pharmacoepidemiology studies compliant with the ENCePP Code of Conduct. The budget of ARS is partially sustained by such studies.

Mar 21, 2023 | mdpi.com | Valentina Lorenzoni |Rosa Gini |Giuseppe Turchetti |Irma Convertino

3. DiscussionThis descriptive exploration of baricitinib and tofacitinib utilization showed that these new drugs were used in accordance with labels [,] and clinical guideline recommendations []. In line with these, JAKi was used at least as a second-line treatment pharmacological approach when csDMARDs alone failed in controlling RA disease.